Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25568370 | 1.00 | CYP4F2 (0.33) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL15237366 | 0.83 | CYP4F2 (0.35) | CYP4F2CYP4A11 | |
| SCHEMBL34475462 | 0.80 | CYP4F2 (0.30) | CYP4F2CYP4A11CYP3A4TSHRCYP2C19 | |
| SCHEMBL25568367 | 0.79 | CYP1A2 (0.34) | — | |
| SCHEMBL25188768 | 0.78 | CYP4F2 (0.50) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL25568327 | 0.77 | CYP4F2 (0.41) | CYP4F2CYP4A11MAPT | |
| SCHEMBL34476313 | 0.76 | CYP4F2 (0.49) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL2633828 | 0.76 | CYP4F2 (0.49) | CYP4F2CYP4A11ALDH1A1MAPTLMNA | |
| SCHEMBL356582 | 0.76 | CYP4F2 (0.34) | CYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL6935574 | 0.76 | CHRNB2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TCOF1, SLC10A2, PAM | CYP4F2 651/4885CYP4A11 2709/4885ALDH1A1 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.